


Online Resource 2 The Trx1/CD30 system is a potential target for translational research into the pharmacological modulation of multiple redox and immunological pathways. Changes in serum, tissue or tumor microenvironment levels of Trx1 and sCD30 are functional extracellular biomarkers of the new target, while Treg/Th1/Th17 cytokine levels are intracellular biomarkers. Being able to manipulate their role in pathological processes may well represent a non-invasive means of redirecting the physiological system towards a beneficial immunological and therapeutic response



Article title: The potential role of thioredoxin1 and CD30 systems as multiple pathway targets and biomarkers in tumor therapy

Journal name: Cancer Immunology and Immunotherapy

Authors names: Anna Maria Berghella, Patrizia Pellegrini, Tiziana Del Beato, Fabiana Ciccone and Ida Contasta

Affiliation: Council of National Research (CNR) - Institute of Translational Pharmacology (IFT) – 67100 L'Aquila-Italy

Corresponding author: Dr. Anna Maria Berghella , e-mail address: annamaria.berghella@cnr.it